BioDuro and Atombeat partner to accelerate AI-powered peptide drug discovery

Ella Day | July 31, 2025 | News story | Mergers and Acquisitions |  AI, BioDuro, Corporate, Devices 

BioDuro and Atombeat have announced a partnership to launch an artificial intelligence (AI)-driven platform designed to accelerate peptide drug discovery from molecular design to preclinical candidates. The collaboration combines BioDuro’s deep expertise in peptide chemistry, biology and drug metabolism and pharmacokinetics with Atombeat’s AI modelling technologies for faster, more cost-effective development of peptide therapeutics.

Specifically, Atombeat’s Hermite and RiDYMO software suite, which enables in-silico exploration of over one trillion peptide compounds, is built from a collection of more than 1,000 natural and non-natural amino acids. These tools combine AI, reinforced dynamics and predictive modelling to efficiently screen candidates based on key traits like membrane permeability – before any lab testing begins.

Once candidates are identified, BioDuro uses its high-throughput synthesis technology to produce hundreds of high-purity peptides within a week, bypassing traditional purification steps. This integration with in-house biology assays enables rapid validation, significantly reducing R&D timelines and costs.

“We are excited to advance peptide innovation through our strategic partnership with Atombeat,” said Armin Spura, CEO of BioDuro. “Together, we aim to deliver smarter, more efficient drug development solutions.”

Dongdong Wang, co-founder of Atombeat, added: “This partnership reflects our commitment to combining AI and experimentation to meet global clinical needs.”

Ella Day

31/7/25